Viatris Inc. · NASDAQ:VTRS
Viatris — Mylan — Merger or Acquisition (July 2020)
11 slides from Viatris's merger presentation, Jul 10, 2020
Slide 1: Establishing a New Kind of Healthcare Company
Establishing a New Kind of Healthcare Company July 2020Establishing a New Kind of Healthcare Company July 2020
Slide 2: Forward-Looking Statements
Forward-Looking Statements This communication contains “forward-looking statements”. Such forward-looking statements may include, without limitation, statements about the proposed combination of Upjohn Inc. (“Newco”) and Mylan N.V. (“Mylan”), which will immediately follow the proposed separation of
Slide 3: Additional Information and Where to Find It
Additional Information and Where to Find It This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale
Slide 4: Non-GAAP Financial Measures
Non-GAAP Financial Measures Mylan is not providing forward looking information for U.S. GAAP reported financial measures or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable U.S. GAAP measure because it is unable to predict with reasonable c
Slide 5: Access Leadership Partnership
ACCESS LEADERSHIP PARTNERSHIP Empowering people worldwide to live healthier, at every stage of life. 5ACCESS LEADERSHIP PARTNERSHIP Empowering people worldwide to live healthier, at every stage of life. 5
Slide 6: Experienced Leadership to Optimize Total Shareholder Return
Experienced Leadership to Optimize Total Shareholder Return O VER A L L S T R A T E G I C BUS I NE S S AND F I NAN CI A L P E RF O R M AN CE O V E RS I GHT AND O P E R AT I O NA L P E RF O R M AN CE AND AND S T RAT EG Y L EA D ER SH I P EXEC U T I O N DI S CI P L I NE + + + D EVEL O P M EN T Robert
Slide 7: Viatris: A New Kind of Healthcare Company
VIATRIS: A New Kind of Healthcare Company A new business model with enhanced global scale and operating platform with expanded commercial capabilities An even stronger financial profile expected • Annual cost synergies of ~$1 billion expected by the fourth full year after close • Strong adjusted EBI
Slide 8: Viatris Will Offer a Unique Global Healthcare Gateway
Viatris Will Offer a Unique Global Healthcare Gateway™ Broad Global Commercial Reach Across Channels & Therapeutic Areas Broad Global Commercial Reach Global Supply & Across Channels & TAs Manufacturing Fueling Network Global Supply & Future Manufacturing Expansive Technical Growth Network Expertise
Slide 9: Clear Roadmap of Execution to Optimize Total Shareholder Return (TSR)
Clear Roadmap of Execution to Optimize Total Shareholder Return (TSR) Years Transaction Close 0 1 2 3 4 5 6 7+ INTEGRATION Operations PRODUCT LAUNCHES ~$3bn Business New Pipeline Execution Launches COST SYNERGIES ~$1b Synergies REVENUE SYNERGIES Leverage RAPID DELEVERAGING SHARE REPURCHASES Capital
Slide 10: Expected Attractive Financial Profile
Expected Attractive Financial Profile VIATRIS Selected Spec Pharma / Generics ü More Balanced Risk Profile ü Robust Balance Sheet 1 ~$20 $17 $12 $8 $8 $7 $1 2020E EBITDA 2 * 5 Margin ~40% 23% 28% 30% 18% 28% 23% Avg. Est. Gross ≤ 2.5x Debt / 2020E ~4x 3 * Sustained leverage target EBITDA Pays Divide
Slide 11: Committed to Corporate Social Responsibility (CSR)
Committed to Corporate Social Responsibility (CSR) Viatris will build upon Mylan’s ongoing multi-faceted approach to corporate responsibility, as well as leverage the strengths of Upjohn’s corporate responsibility work PATIENT ENVIRONMENTAL HEALTH HEALTH An industry leader with products that are cap